| Today’s Big NewsFeb 13, 2024 |
|
Wednesday, February 28, 2024 | 11am ET / 8am PT While oral minitablets can offer several advantages in pharmaceutical applications, manufacturing them can be a complex challenge. Join industry experts for a discussion on the intricate journey of drug development, with a look at how minitablets have redefined formulation strategies, efficacy, patient-centric solutions, options for lifecycle management, and more. Sign up now! 
|
|
| By Annalee Armstrong If you ask Pfizer’s chief scientist Mikael Dolsten, M.D., Ph.D., what the next pandemic will be, you may be surprised at the answer. It’s not viral or respiratory, and, in fact, it’s here now. |
|
|
|
By Fraiser Kansteiner With four new drug launches rolling and the majority of the company’s losses of exclusivity in the rearview, Biogen figures it could chart continued revenue growth over the next 10 years, CEO Chris Viehbacher said Tuesday. |
By Gabrielle Masson Roivant’s Hemavant has discontinued development of its only asset, a former Eisai drug dubbed RVT-2001 that was being studied in a midstage trial for patients with myelodysplastic syndromes. |
By Andrea Park As Philips reaches a consent decree agreement with the FDA that will temporarily suspend its sales of sleep therapy devices in the U.S., competitor ResMed, meanwhile, is ramping up its product offerings. |
|
Thursday, March 21, 2024 | 11am ET / 8am PT Join us for a discussion on the evolution of HCP engagement through the lens of Customer Science – the integration of data science, behavioral science, and AI. In this webinar, we explore how Customer Science brings substantial benefits to commercial leaders, providing a deeper understanding of HCPs and patients for more effective engagement. Register now. 
|
|
By Kevin Dunleavy In a decision that bodes well for the Biden administration’s push to rein in drug prices, a federal judge in Texas has tossed a lawsuit from industry lobbying group PhRMA which challenged the legality of Medicare price negotiations as drawn up in the Inflation Reduction Act (IRA). |
By Annalee Armstrong AI drug hunter Exscientia has fired CEO Andrew Hopkins effective immediately after the board determined he had engaged in two personal relationships with employees that were deemed “inappropriate and inconsistent” with company values. |
By Angus Liu Buoyed by JAK inhibitor market-leader Jakafi and its cream counterpart Opzelura, Incyte crossed the $1 billion threshold in quarterly revenues for the first time. But only one of the drugs met Wall Street’s expectations. |
By Gabrielle Masson Bristol Myers Squibb is offering VantAI up to $674 million biobucks in a new partnership aimed at designing molecular glues as small-molecule therapeutics. |
By Conor Hale The company announced it has completed an early, first-in-human trial of a sensor-equipped cardiac implant that can listen to the sounds of a beating heart for the bubbling of a leaky valve or signs of other conditions. |
By Fraiser Kansteiner Roughly half a year after Biogen’s $7.3 billion buyout of rare disease specialist Reata Pharmaceuticals, the companies’ blockbuster bid for Reata’s Friedreich’s ataxia (FA) drug Skyclarys is starting to take shape. |
By Andrea Park After a successful limited rollout of its newest insulin pump in the U.S., Tandem Diabetes Care is picking up the pace. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we explore the most anticipated drug launches of 2024. Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028. |
|
|---|
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
